Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Pain Med ; 22(4): 807-818, 2021 04 20.
Article in English | MEDLINE | ID: mdl-33779730

ABSTRACT

OBJECTIVE: For many medical professionals dealing with patients with persistent pain following spine surgery, the term Failed back surgery syndrome (FBSS) as a diagnostic label is inadequate, misleading, and potentially troublesome. It misrepresents causation. Alternative terms have been suggested, but none has replaced FBSS. The International Association for the Study of Pain (IASP) published a revised classification of chronic pain, as part of the new International Classification of Diseases (ICD-11), which has been accepted by the World Health Organization (WHO). This includes the term Chronic pain after spinal surgery (CPSS), which is suggested as a replacement for FBSS. METHODS: This article provides arguments and rationale for a replacement definition. In order to propose a broadly applicable yet more precise and clinically informative term, an international group of experts was established. RESULTS: 14 candidate replacement terms were considered and ranked. The application of agreed criteria reduced this to a shortlist of four. A preferred option-Persistent spinal pain syndrome-was selected by a structured workshop and Delphi process. We provide rationale for using Persistent spinal pain syndrome and a schema for its incorporation into ICD-11. We propose the adoption of this term would strengthen the new ICD-11 classification. CONCLUSIONS: This project is important to those in the fields of pain management, spine surgery, and neuromodulation, as well as patients labeled with FBSS. Through a shift in perspective, it could facilitate the application of the new ICD-11 classification and allow clearer discussion among medical professionals, industry, funding organizations, academia, and the legal profession.


Subject(s)
Chronic Pain , Failed Back Surgery Syndrome , Chronic Pain/diagnosis , Failed Back Surgery Syndrome/diagnosis , Humans , International Classification of Diseases , Pain Management , Spine
2.
Chemosphere ; 122: 32-37, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25434272

ABSTRACT

Volatile organic compounds (VOCs) enter indoor environments through internal and external sources. Indoor air concentrations of VOCs vary greatly but are generally higher than outdoors. Plants have been promoted as indoor air purifiers for decades, but reports of their effectiveness differ. However, while air-purifying applications may be questionable, the waxy cuticle coating on leaves may provide a simple, cost-effective approach to sampling indoor air for VOCs. To investigate the potential use of plants as indoor air VOC samplers, a static headspace approach was used to examine the relationship between leaf and air concentrations, leaf lipid contents and octanol-air partition coefficients (Koa) for six VOCs and four plant species. The relationship between leaf and air concentrations was further examined in an actual residence after the introduction of several chlorinated VOC emission sources. Leaf-air concentration factors (LACFs), calculated from linear regressions of the laboratory headspace data, were found to increase as the solvent extractable leaf lipid content and Koa value of the VOC increased. In the studies conducted in the residence, leaf concentrations paralleled the changing air concentrations, indicating a relatively rapid air to leaf VOC exchange. Overall, the data from the laboratory and residential studies illustrate the potential for plant leaves to be used as cost effective, real-time indoor air VOC samplers.


Subject(s)
Air Pollutants/analysis , Environmental Monitoring/methods , Plant Leaves/chemistry , Volatile Organic Compounds/analysis , Air Pollution, Indoor/analysis , Linear Models , Magnoliopsida/chemistry
4.
Spine (Phila Pa 1976) ; 30(24): 2709-16, 2005 Dec 15.
Article in English | MEDLINE | ID: mdl-16371892

ABSTRACT

STUDY DESIGN: A prospective, randomized, controlled, multicenter clinical study. OBJECTIVE: To compare the safety and clinical and radiographic outcomes of OP-1 (BMP-7) Putty to autogenous iliac crest bone graft in a population of patients undergoing laminectomy and posterolateral fusion for symptomatic lumbar stenosis associated with degenerative spondylolisthesis. SUMMARY OF BACKGROUND DATA: Although the existing preclinical and clinical data suggest that OP-1 is able to achieve osteoinduction and clinical fusion in a variety of situations, the efficacy of this recombinant protein in a clinical spine fusion population has not been fully elucidated. This study directly compares the efficacy and safety of OP-1 putty to autograft bone for arthrodesis in patients with symptomatic stenosis in association with degenerative spondylolisthesis. METHODS: Thirty-six patients with degenerative lumbar spondylolisthesis and symptoms of neurogenic claudication underwent laminectomy, bilateral medial facetectomy, and posterolateral fusion using either iliac crest autograft or OP-1 Putty. Oswestry scores and SF-36 questionnaires were used to determine the clinical response to treatment. Independent, blinded neuroradiologists reviewed both static and dynamic radiographs to determine the fusion status. Successful fusion was declared whenthe presence of continuous bridging bone between the transverse processes was observed and less than 5 degrees of angular motion and 2 mm of translational movement was measured using digital calipers. RESULTS: Efficacy data were tabulated for 27 patients at the 24-month time point and an additional 4 patients (without evaluable 24-month results) at the 36-month time point. One patient was not evaluable for radiology, so the data reflect clinical information for 31 patients and radiology for 30 patients. Clinical success, defined as a 20% improvement in the preoperative Oswestry score, was achieved by 17 of 20 (85%) OP-1 Putty patients and 7 of 11 (64%) autograft patients. A successful posterolateral fusion was achieved in 11 of 20 (55%) OP-1 Putty patients and 4 of 10 (40%) autograft patients. SF-36 scores showed similar clinical improvement in both groups. No systemic toxicity, ectopic bone formation, recurrent stenosis, or other adverse events specifically related to the use of the OP-1 Putty implant were observed. CONCLUSION: This study represents the first clinical trial to demonstrate the safety and similarity of OP-1 Putty as a replacement for autogenous bone graft in the posterolateral fusion environment with a minimum of 2-year follow-up. OP-1 Putty was able to achieve osteoinduction leading to a radiographically solid fusion in the absence of autogenous iliac crest bone graft in 55% of the patients at 24 and 36 months. These results compare favorably to the historical fusion rates reported for uninstrumented arthrodesis in this challenging clinical scenario.


Subject(s)
Arthrodesis/methods , Bone Morphogenetic Proteins/administration & dosage , Bone Transplantation/methods , Ilium/transplantation , Lumbar Vertebrae/surgery , Transforming Growth Factor beta/administration & dosage , Adult , Aged , Aged, 80 and over , Bone Morphogenetic Protein 7 , Female , Follow-Up Studies , Humans , Lumbar Vertebrae/diagnostic imaging , Lumbar Vertebrae/drug effects , Male , Middle Aged , Pilot Projects , Prospective Studies , Radiography , Transplantation, Autologous/methods
5.
Spine (Phila Pa 1976) ; 29(17): 1885-92, 2004 Sep 01.
Article in English | MEDLINE | ID: mdl-15534410

ABSTRACT

STUDY DESIGN: A prospective, randomized, controlled, multicenter clinical study was conducted. OBJECTIVE: To compare the clinical and radiographic outcomes of patients treated with OP-1 (BMP-7) Putty to autogenous iliac crest bone graft for one-level uninstrumented posterolateral fusion of the lumbar spine following decompressive laminectomy for the treatment of symptomatic degenerative spondylolisthesis with spinal stenosis. BACKGROUND: Preclinical studies have demonstrated that osteoinductive recombinant human osteogenic protein 1 in the form of OP-1 Putty is successful at achieving a posterolateral fusion in rabbits and dogs without any significant safety concerns. METHODS: Thirty-six patients with degenerative lumbar spondylolisthesis and symptoms of neurogenic claudication were randomized (2:1) to either OP-1 Putty (3.5 mg of OP-1 per side) or autogenous iliac crest bone graft for one-level uninstrumented posterolateral fusion following a decompressive laminectomy. Enrollment in the study was complete when 24 OP-1 Putty patients and 12 autograft patients had been randomized and treated. A patient administered Oswestry scale and SF-36 scale were used to determine clinical outcomes. Independent, blinded neuroradiologists reviewed both static and dynamic radiographs to determine fusion status. RESULTS: At the 1-year follow-up, 32 patients were available for clinical analysis and 29 patients were available for radiographic review. Clinical success as measured on the Oswestry scale was achieved by 18 of 21 (86%) OP-1 Putty patients and 8 of 11 (73%) autograft patients. SF-36 pain index scores showed similar results. Fourteen of 19 (74%) OP-1 Putty patients and 6 of 10 (60%) autograft patients achieved a successful posterolateral fusion fulfilling all fusion criteria. Of the 29 evaluable patients, 15 were both clinical and radiographic successes, 5 were radiographic successes but were clinical failures, 1 patient was both a radiographic and clinical failure, and 8 patients were radiographic failures but were clinical successes. No systemic toxicity, ectopic bone formation, recurrent stenosis, or other adverse events related to the OP-1 Putty implant were observed. CONCLUSION: Although the posterolateral spine is a challenging fusion environment in patients with degenerative spondylolisthesis, successful radiographic fusion was obtained using OP-1 Putty at a rate that was similar to autograft given the number of patients in this study. Importantly, there were no apparent adverse consequences related to the use of the OP-1 Putty implant in this patient population.


Subject(s)
Bone Morphogenetic Proteins/therapeutic use , Bone Substitutes/therapeutic use , Lumbar Vertebrae/surgery , Spinal Fusion/methods , Spinal Stenosis/surgery , Spondylolisthesis/surgery , Adult , Aged , Aged, 80 and over , Biocompatible Materials , Bone Morphogenetic Protein 7 , Bone Morphogenetic Proteins/administration & dosage , Bone Substitutes/administration & dosage , Bone Transplantation , Carboxymethylcellulose Sodium/administration & dosage , Carboxymethylcellulose Sodium/therapeutic use , Collagen Type I/administration & dosage , Collagen Type I/therapeutic use , Decompression, Surgical , Female , Follow-Up Studies , Humans , Laminectomy , Male , Materials Testing , Middle Aged , Pilot Projects , Prospective Studies , Radiography , Recombinant Proteins/administration & dosage , Recombinant Proteins/therapeutic use , Single-Blind Method , Spinal Stenosis/diagnostic imaging , Spinal Stenosis/etiology , Spondylolisthesis/complications , Spondylolisthesis/diagnostic imaging , Transplantation, Autologous , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...